Although there is a lot known about Waldenströms macroglobulinemia (WM), there is little understanding of the wild-type and IgM-related disorders. During this interview, Steven Treon, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, highlights the lack of comprehension surrounding the pathogenesis of wild-type and IgM related WM. He emphasizes that in order to utilize our genomic knowledge, more research and studies need to be carried out to improve current therapies. This video was recorded at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.
